# XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

Source: https://onco.cc/trials/nct06936527/  
OnCo record `nct06936527` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in colorectal cancer, run by NovaOnco Therapeutics Co., Ltd., now recruiting.

## Summary

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation is a phase 1/2, randomised interventional study registered as NCT06936527 by NovaOnco Therapeutics Co., Ltd., with a registry enrolment figure of 102 participants, started 2025-05-23 and due to reach its primary completion in 2028-04-30. Interventions recorded: Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI; Drug: XS-03; Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI. Conditions listed: Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation. Primary outcome: Phase 1b: Number of participants with Dose-limiting Toxicities (DLTs) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab; Phase 1b: Determine the Maximum Tolerated Dose (MTD) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab; Phase 2: . Colorectal eligibility wording from the registry: "Patients with histologically and/or cytologically confirmed metastatic colorectal cancer who are not suitable for surgical treatment". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: XS-03-II201
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06936527
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase Ib/II Clinical Study: Aim to Valuate the Efficacy and Safety of XS-03 Comination With FOLFOX or FOLFIRI and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
- Sponsor: NovaOnco Therapeutics Co., Ltd.
- Enrolled: 102

## Sources

- ClinicalTrials.gov NCT06936527: https://clinicaltrials.gov/study/NCT06936527

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06936527.json